Compare Danaher Corporation (DHR) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs ProShares Ultra QQQ ETF — how do they compare? Danaher Corporation trades at $219.27 (market cap $152.87B), while ProShares Ultra QQQ ETF trades at $98.67 (market cap $15.38B). The key difference: Danaher Corporation is far larger — about 9.9× ProShares Ultra QQQ ETF's market cap, and Danaher Corporation pays a 0.74% dividend while ProShares Ultra QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and ProShares Ultra QQQ ETF for 37 Days on average.
| DHR | QLD | |
|---|---|---|
Market Cap | $152.87B | $15.38B |
Volume | 5,228,698 | 4,844,085 |
Sector | Health | Leveraged / Inverse |
52-Week High | $242.05 | $100.77 |
52-Week Low | $161.91 | $57.16 |
Typical Hold Time | 69 Days | 37 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
QLD trades at $100.23, down 0.54% on the day, with technical indicators showing a bullish moving average signal but overbought RSI conditions. The ETF maintains support at $99 and resistance at $101, with institutional buying activity noted in recent filings. Recent news highlights QLD's resilience compared to more leveraged alternatives during market downturns.
The outlook remains cautiously optimistic given strong technical momentum, though overbought conditions suggest potential near-term consolidation. Key risks include Federal Reserve policy impacts and Nasdaq volatility, while institutional accumulation supports medium-term bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
